Should minophagen (glycyrrhizin) be used as primary therapy for anti‑tuberculosis drug‑induced hepatitis?

Minophagen (Glycyrrhizin) Should NOT Be Used as Primary Therapy for Anti-TB Drug-Induced Hepatitis

The primary management of anti-TB drug-induced liver injury (DILI) is immediate withdrawal of hepatotoxic drugs, not the addition of glycyrrhizin preparations like minophagen. The 2016 ATS/CDC/IDSA guidelines make no mention of glycyrrhizin as a treatment modality for anti-TB DILI 1.

Critical Evidence Gap

The FDA drug labels provided 2 describe magnesium sulfate, not minophagen/glycyrrhizin—this appears to be a labeling error in the evidence database. Actual minophagen contains glycyrrhizin, not magnesium sulfate.

What the Guidelines Actually Recommend

The authoritative 2016 guideline 1 establishes a clear management algorithm for anti-TB DILI:

For Established DILI:

• Stop all hepatotoxic drugs immediately when ALT rises >3× upper limit of normal with symptoms or >5× without symptoms
• Clinical monitoring with aminotransferases and total bilirubin every 1-4 weeks for the first 2-3 months
• Consider alternative regimens that minimize hepatotoxic agents while preserving efficacy

Alternative Regimens (in order of preference):

1. Without pyrazinamide: INH + RIF + EMB for 2 months, then INH + RIF for 7 months
2. Without INH and PZA: RIF + EMB + fluoroquinolone for 12-18 months (for advanced liver disease)
3. Without INH: RIF + PZA + EMB ± fluoroquinolone for ≥6 months
4. Minimal hepatotoxicity: EMB + fluoroquinolone + cycloserine + injectable for 18-24 months (for severe unstable liver disease)

The Research Evidence on Glycyrrhizin

While a 2022 network meta-analysis 3 suggests magnesium isoglycyrrhizinate (MGIG) may be effective for treating established anti-TB DILI (RRs 1.15-1.72), this evidence has critical limitations:

• No guideline endorsement: The study itself acknowledges "clinical guidelines and expert consensus do not yet recommend glycyrrhizic acid preparations" 3
• Geographic bias: Evidence predominantly from Chinese databases
• Publication bias: Authors note "predominance of positive findings that may reflect publication bias" 4
• Lack of standardization: Heterogeneous study designs and outcomes 4

Safety Concerns

Glycyrrhizin preparations carry their own risks 4:

• Pseudoaldosteronism (hypertension, hypokalemia, edema)
• Drug interactions with anti-TB medications
• May complicate monitoring of underlying liver injury

Clinical Algorithm

When ALT/AST elevation occurs during anti-TB therapy:

1. Measure severity: Check ALT, AST, total bilirubin, INR
2. Stop hepatotoxic drugs if ALT >3× ULN with symptoms OR >5× ULN without symptoms
3. Provide supportive care: Monitor liver function, ensure adequate nutrition (low albumin <3.5 g/dL and prealbumin <20 mg/dL are risk factors) 5
4. Wait for normalization: Allow transaminases to return to normal
5. Sequential reintroduction: Start with least hepatotoxic drug (typically rifampin first), then add others incrementally
6. Consider alternative regimens if reintroduction fails or patient has severe liver disease

Do NOT add glycyrrhizin as primary therapy—the evidence is insufficient and it is not guideline-recommended 1, 3.

Common Pitfalls

• Continuing hepatotoxic drugs: The most critical error is failing to stop offending agents promptly
• Adding unproven therapies: Glycyrrhizin may delay appropriate management and add unnecessary risks
• Inadequate monitoring: Patients with baseline liver disease need weekly monitoring for first 2-3 months 1
• Ignoring risk factors: Age >45, female sex, alcohol use, viral hepatitis, and malnutrition significantly increase DILI risk 5

The evidence strongly supports drug withdrawal and supportive care as the cornerstone of anti-TB DILI management, not the addition of glycyrrhizin preparations.